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Abstract
Introduction
Post mastectomy radiation therapy can cause significant skin reaction for patients treated with
bolus. The elimination of bolus as a standard practice for this treatment has been suggested in
recent literature. Additionally, volumetric modulated arc therapy (VMAT) may deliver a
comparable plan with the benefit of reducing treatment times for this population compared to
static field intensity modulated radiation therapy (IMRT).
Methods
This study is a retrospective dosimetric analysis of ten right-sided postmastectomy radiation
therapy patients. The subjects had previously completed a course of radiation therapy consisting
of static field IMRT with the use of bolus every other day (qod). The researcher used the same
data set and planning objectives to create two VMAT plans. One VMAT plan consisted of
continuous arcs, while the other consisted of partial arcs with predefined avoidance sectors.
Each VMAT plan was created without the use of bolus.
Results
Numeric data was collected and statistical analysis was performed. Non-parametric Wilcoxson
Signed Ranks tests were completed to compare difference in means between IMRT qod bolus
and both VMAT full arc and VMAT partial arc. Results are given for planning target volumes,
organs at risk, and a skin rind contour.
Conclusion
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Static field IMRT qod bolus and VMAT no bolus plans have comparable dosimetric results. Of
clinical significance is that all plans met clinical goals. Skin dose was found to be less in VMAT
plans with a statistically significant difference compared to IMRT qod bolus. Nonetheless, skin
dose was found to be of an appropriate dose for decrease in toxicity and comparable local
control.
Keywords: post mastectomy radiation therapy, bolus, skin dose, static field intensity modulated
radiation therapy, volumetric modulated arc therapy, full arc, partial arc

Introduction
Breast cancer is the most commonly diagnosed cancer in women, and radiation treatment
techniques are continually advancing for this population. With 1 in 8 women in the United States
developing breast cancer in her lifetime,1 it is essential that treatment is effective, and treatment
related toxicities minimized.
The breast lies on the anterior chest wall atop the pectoralis major muscle. It extends
from the 2 rib to the inframammary fold around the level of the 6 rib. Medially the breast
nd
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extends to the lateral edge of the sternum, and laterally it extends to the midaxillary line.2 The
breast is primarily composed of lobules, ducts, and fatty tissue. Breast cancer can begin in any of
these locations within the breast and are given their name based on this location. In the early
stages, when breast cancers stay within the ducts or lobules, they are called carcinoma in situ.
Without diagnosis and treatment these cancers become invasive, meaning they extend through
the membrane and into surrounding breast tissue. At 80%, the most common invasive breast
cancer is invasive ductal carcinoma,1 followed by invasive lobular carcinoma. Another subtype
of breast cancer worth noting is inflammatory breast cancer. This subtype is more rare, but it is
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also more aggressive and more likely to spread.2 Other less common breast cancers include
medullary carcinoma, mucinous carcinoma, Paget disease of the nipple, phyllodes tumor, and
tubular carcinoma.3
There are three major lymph nodes chains associated with the breast: axillary, internal
mammary, and supraclavicular. It is via these lymph node chains that breast cancers can spread,
or metastasize, outside the breast. Most frequently involved are the axillary nodes, followed by
the internal mammary nodes, and lastly the supraclavicular nodes. 2
Treatment for breast cancer is highly catered to the individual patient with treatment
options including the following: surgery, radiation therapy, chemotherapy, hormone therapy, and
targeted therapies.1 Surgery is commonly the initial treatment for breast cancer regardless of the
extent of disease. Surgical options include lumpectomy or mastectomy. Lumpectomy is the
surgical removal of the tumor and a small amount of surrounding tissue with conservation of the
breast. Conversely, mastectomy is the removal of all the breast tissue. During either procedure,
the surgeon will remove lymph nodes for testing to determine if there is nodal involvement. This
will help in determining what treatment is needed post-operatively.1 The decision for a breast
cancer patient to undergo either a lumpectomy or a mastectomy can be based on several factors.
A mastectomy is often recommended for multifocal disease, if the tumor is larger than 5cm, or if
the removal of a tumor from a small breast will leave the patient with little remaining breast
tissue. If a lumpectomy has been performed but the cancer remains at the surgical margins, a
mastectomy may be needed. A mastectomy may be indicated based on genetic factors as well.
Inherited gene mutations such as a BRCA1 or BRCA2 mutation can increase risk of developing a
second breast cancer. Patient-related reasons for undergoing mastectomy include inherited gene
mutations, prior radiation to the involved breast, diseases including lupus or rheumatoid arthritis,
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and factors that contraindicate post-surgical radiation including pregnancy or inability to commit
to daily radiation therapy treatment. Some patients may choose mastectomy for greater peace of
mind.1
Radiation therapy is recommended for patients post-operatively to reduce the risk of
cancer recurrence. For patients who undergo mastectomy, this is called post-mastectomy
radiation therapy (PMRT). Factors for which patients may be recommended PMRT include
tumor size, positive surgical margins, and lymph node involvement. 1 PMRT has been shown to
improve outcomes for women with node positive breast cancer, with one trial showing a risk
reduction of 32% for locoregional recurrence.2
The goal of PMRT is to eradicate disease within the chest wall and regional lymph node
chains. Radiation therapy is delivered using photons which tend to have a skin sparing effect,
unlike earlier Cobalt-60 units which treated more superficially. To combine the favorable
superficial dose of Cobalt-60 and modern photon therapy, bolus was introduced. Bolus is a tissue
equivalent material that shifts the 95-100% isodose lines toward the skin surface, allowing for
dose that would otherwise be missed in the build-up region.4 A study was done in 2007 which
looked at radiation oncologist use of bolus in the setting of PMRT. The results showed that 6%
never used bolus, 68% always used chest wall bolus, and 26% used bolus only for specific
indications.5 The unfortunate side effect of bolus use for the patient is increased skin reaction.
Data gathered from 13 PMRT studies revealed a grade 3 acute toxicity risk of 9.6% with bolus
compared to 1.2% without bolus.4 Another study showed similar results with a grade 2 skin
reaction risk of 40% in patients receiving bolus compared to 21% for those without bolus.6 Grade
2/3 skin reactions have also been associated with increased need for radiation treatment
interruptions which pose a risk to local control. 5 Looking at bolus use and local recurrence after
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PMRT, results are comparable with a rate of 3.5% with bolus compared to 3.6% without bolus. 4
The clear conclusion among current research regarding use of bolus in PMRT is simply
summarized as “PMRT without bolus had the clinical advantage of reducing the skin dose and
resulting in no severe acute radiation dermatitis without increasing the recurrence rates.”7 The
international consensus as reported by Kaidar-Person echoed this statement. They concluded that
bolus increases side effects and does not improve local control for patients without a high risk of
skin involvement. They found that bolus still plays a role in the PMRT setting in select cases.
These cases include the following: inflammatory breast cancer, DCIS or invasive breast cancer
with superficial margins, inoperable or fungating masses, and the treatment of breast cancer
recurrence.4
Abshire summarizes the goal of radiation therapy nicely when she states it as “to safely
increase the amount of radiation dose a tumor receives, and to protect healthy tissues from the
dose to reduce toxicity to the site.” There have been numerous advancements in the field, starting
with the introduction of high energy megavoltage x-rays as compared to the earlier low-energy
x-rays of Cobalt radiation.8 Three-dimensional radiotherapy (3DCRT) was used for years, and it
is still advantageous in many clinical situations. For PMRT, 3DCRT is limited in that it yields
sub-optimal target coverage and increased dose to surrounding healthy tissue.9 Intensity
Modulated Radiation Therapy (IMRT) was a standout advancement in radiation therapy delivery.
IMRT allows for increased conformity of radiation treatment. It does this by shaping the
individual beams during treatment delivery rather than delivering radiation through a static
shape.8 Another advancement in radiation therapy treatment delivery is called volumetric
modulated arc therapy (VMAT). This is a complex type of IMRT which involves the continuous
delivery of radiation as the gantry rotates, as opposed to the step and shoot gantry movement of
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static field IMRT. VMAT has become widely used for radiation treatment of several cancer sites
including the brain, head and neck, abdomen and thorax. However, the use of VMAT in breast
cancer treatment has been limited.10 Several studies have been done which looked at the use of
VMAT in the treatment of breast cancer. A study by Iorio found good dosimetric results in breast
cancer patients both after breast conserving surgery and post mastectomy. 9 A study by Zhang
described several benefits of VMAT as compared with IMRT in PMRT. These benefits include
the following: dose coverage and homogeneity of the planning tumor volume (PTV), reduced
mean dose and volumes of the lung and heart, and decreased monitor units (MU) and treatment
time. Simply stated, the VMAT plan was superior to the IMRT plan. 11
The purpose of this study is to evaluate the efficacy of a VMAT plan without bolus for
PMRT compared to the standard static field IMRT plan with bolus placement every other day
(qod) in a Midwest Radiation Oncology center. The researcher evaluated the plans based on the
standard dose constraints and an additional measurement of mean dose in the rind of tissue
between the skin and the treated chest wall volume. The hypothesis of the research is that a
VMAT plan without bolus would deliver a comparable plan with a comparable skin dose as
static field IMRT with qod bolus for PMRT. The impact of this study is a potential decrease in
planning time, shorter treatment times, and reduced patient skin toxicity, all while maintaining
similar outcomes.

Methods
Patient Selection
This study is a retrospective dosimetric analysis of ten patients treated with
postmastectomy radiation therapy at a Midwest radiation oncology center. All subjects were
7

previously treated with a prescription of 180cGy x 28 fractions for a total of 5040cGy to the right
chest wall and regional lymph nodes. Boost treatment was not applicable to this study and
therefore was not considered in the patient selection process. The technique utilized for the
patient’s treatment was static field IMRT with superflab bolus qod. All patients were 18 years of
age or older. Exclusion criteria included male patients, bilateral breast cancer diagnosis,
inflammatory breast cancer diagnosis, and patients with tissue expanders or pacemakers. Patients
were identified as potential subjects with the aid of a spreadsheet that the radiation oncology
center houses. With this spreadsheet, the researcher was able to identify patients who received
PMRT to the right chest wall. At that point, charts were accessed to determine that the remaining
criteria were met. This process was repeated until ten patients were selected for the study.
Institutional Review Board (IRB)
A request for Determination of Human Subject Research was submitted to a Midwest
hospital. It was determined that this research did fit the definition of human subject research and
therefore required IRB approval/oversight. An application was submitted under the exempt
review category and subsequently approved. The following Collaborative Institutional Training
Initiative (CITI) courses were also required and completed: Human Subject Research and
Conflict of Interest. The study was also approved by the Grand Valley State University (GVSU)
IRB.
Simulation/Patient Positioning
Patients were simulated using a GE CT simulator. Patients were positioned headfirst and
supine. Patient immobilization included a wing board and a custom vacuum bag for head and
arm support. The patient head was turned to the left (away from the affected side) and arms
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raised above head. A cushion was placed under patient knees for support. The physician placed
radiopaque markers on the patient skin at the superior and inferior treatment margins and across
the mastectomy scar. Patients were scanned free breathing and 2.5cm slice thickness. Scan
borders included superior to the patient's chin, inferior to include the inferior skin marker and the
entire lung volume, and laterally to encompass the width of the body.
Planning
Original Treatment Plan: IMRT qod bolus
The original radiation plans used for treatment were generated using Varian Eclipse
version 16.1 Treatment Planning System (TPS). No patients required image registration. Organ
at risk (OAR) contours were created by the planning dosimetrist and verified by the radiation
oncologist, and planning target volume (PTV) contours were delineated by the radiation
oncologist. OARs included heart and ipsilateral lung. PTVs included right chest wall, axillary
and supraclavicular lymph nodes, and internal mammary lymph nodes. PTVs were cropped from
the body surface and labeled PTV_Chestwall_R, LN_Sclav_Ax_R, and LN_IMN_R,
respectively. The amount of crop was 3mm for six patients and 4mm for four patients. Contours
were reviewed for consistency for the study, and no changes were made. The original static field
IMRT qod bolus plan consisted of a fourteen-fraction no bolus plan and a fourteen-fraction bolus
plan. After these plans were created individually, each using the same contours as described
above, a plan sum was created. This composite plan was then analyzed and evaluated. The bolus
plan utilized 0.5cm bolus for eight patients and 1.0cm bolus for two patients. Eight plans
consisted of six static IMRT beams, one plan had five beams, and one plan had seven beams.
The beam energy used for all plans was 6MV. Flash was not incorporated in the planning
process per the direction of the physician and medical physicist.
9

VMAT Planning
Each original no bolus treatment plan was copied and pasted in the TPS by the researcher
to use as the basis for VMAT planning. This was done to maintain consistencies in planning,
which included planning for the same linear accelerator and at the same isocenter. The plan was
copied and pasted twice, as the study created two separate VMAT plans for comparison to the
static field IMRT qod bolus plan. The most medial and most lateral gantry angles were noted,
along with their associated collimator angles. The IMRT fields were then deleted, and the
prescription was updated to reflect the appropriate dose and fractionation.
A new field was created with 6MV energy, and the arc geometry tool was utilized to
create a plan with one isocenter and two half arcs. Arc properties were defined such that the start
and stop gantry angles matched the previously noted gantry angles. Complement collimator
angles were defined based on the previously noted collimator angles with the medial beam
collimator angle applied to the counterclockwise arc and the lateral beam collimator angle
applied to the clockwise arc. Because the VMAT plans were copied from the previously
optimized static field IMRT plan, the optimizer held constraint information. This information
was deleted prior to initiation of the first optimization. Jaw tracking was disabled for all plans to
maintain consistency to the original plan. Plans were optimized and objectives were modified as
needed until PTV coverage were met and OAR constraints were either met or within an
acceptable margin. For consistency, all VMAT plans were normalized to 100% covers 90% of
target volume. To avoid introduction of bias, no plans were allowed excess planning time.
The first plan was labeled VMAT full arc. These plans used two continuous arcs. The
second plan was labeled VMAT partial arc. These plans used the identical start and stop gantry
angles and collimator angles as the VMAT full arc, but instead utilized four arcs with an
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avoidance sector. The addition of the avoidance sector was based on a technique established by a
2017 study by Munshi.10 The avoidance sector, as defined by Munshi, excluded angles between
30 degrees medial and lateral of the start and stop angles. Refer to Figure 1 for a 3D visualization
of beam configuration for each plan.
Planning Objectives
All plans shared the same objectives as follows:
(1) PTV
a. PTV_Chestwall_R: V100%>95-90%, V95%>95%, Max<110%, V105%<1520%
b. LN_Sclav_Ax_R: V4500cGy>95%
c. LN_IMN_R: V4500cGy>95%
(2) OARs
a. Lung_R: V2000cGy<30-35%, V1000cGy<35-55%, V500cGy<50-65%
b. Heart: D0.03cc<2500cGy, V1500cGy<10%, Mean <130-400cGy
Skin Rind
To not introduce bias, an additional contour was created for each patient at the conclusion
of planning. This contour was labeled “Skin Rind” (Figure 2) and consisted of the rind of tissue
between the body and the PTV_Chestwall_R. The thickness of this rind of tissue varied based on
the amount of skin cropping done to the PTV_Chestwall_R contour. The skin rind was 3mm
thick for six patients and 4mm thick for four patients. This contour was used to determine skin
dose mean for all plans.
Data Analysis
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Data was collected from the dose volume histogram (DVH) and dose statistics from each
plan. Numeric data was transferred to an Excel spreadsheet for statistical analysis. Statistical
analysis consisted of paired samples Wilcoxon Signed Ranks tests. These tests are nonparametric
which means a normal distribution could not be assumed. Wilcoxon Signed Ranks tests were
selected to compare differences in means of the planning objectives and skin rind between static
field IMRT qod bolus and each of the VMAT plans. The software used for statistical analysis
was IBM SPSS Statistics Version 24.

Results
The purpose of this study was to determine if static field IMRT qod bolus and VMAT no
bolus plans in PMRT yielded comparable dosimetric results. Ten patients previously treated with
static field IMRT qod bolus were selected. The average age of these patients at the time of
treatment was 60 years, with a range from 48 years to 77 years of age. A measurement of patient
separation at the central axis ranged from 19.6cm to 30.5cm with a mean of 23.4cm. A total
planning volume was created by combining the PTV_Chestwall_R, LN_Sclav_Ax_R and
LN_IMN_R. The total planning volume for these patients ranged from 243cc to 1090cc with a
mean of 631cc. For each patient, two VMAT plans were generated for comparison to the original
static field IMRT qod bolus plan. Mean total monitor units needed to deliver the static field
IMRT qod bolus plan was 1018 compared to 451 and 357 for the VMAT full arc plan and the
VMAT partial arc plan, respectively. Statistical analysis was performed to compare differences
in means of standard dose constraints and mean skin dose between these plans. Complete results
of Wilcoxon Signed Ranks tests can be found in Table 1 and Table 2 in the appendix.
Planning Target Volumes
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The PTV_Chestwall_R was evaluated based on the following planning objectives:
V100%, V95%, Max, and V105%, where the percentage describes the volume of PTV covered
by that isodose line. There was found to be a statistically significant difference in means for both
the V100% and the V95% when comparing the static field IMRT qod bolus plan and each
VMAT plan. IMRT qod bolus (M=96.14, SD=1.79) reported significantly higher coverage of the
PTV_Chestwall_R with the 100% isodose line than the VMAT full arc (M=90.00, SD=0.00) and
VMAT partial arc (M=90.00, SD=0.00), Z=-2.805, p=0.005. The same is true for V95%,
reporting significantly higher coverage of the PTV_Chestwall_R with the 95% isodose line for
IMRT qod bolus (M=99.91, SD=0.12) than VMAT full arc (M=99.14, SD=0.47) and VMAT
partial arc (M=98.69, SD=0.67), Z=-2.803, p=0.005. See Figure 3 in the appendix for a box plot
displaying the coverage of the PTV_Chestwall_R.
The PTV_Chestwall_R was also evaluated for maximum dose (Max) and V105%. The
Wilcoxson Signed Ranks test found a difference in means for the Max IMRT qod bolus
(M=108.13, SD=1.48) to be significantly lower than VMAT full arc (M=109.34, SD=1.04) Z=2.090, p=0.037. There was no statistically significant difference in means for the Max between
IMRT qod bolus and VMAT partial arc (M=109.21, SD=0.99), Z=-1.580, p=0.114. There was no
statistically significant difference in means between IMRT qod bolus (M=7.24, SD=8.93) and
either the VMAT full arc (M=9.04, SD=5.41), Z=-0.459, p=0.646 or the VMAT partial arc
(M=16.19, SD=8.58), Z=-1.886, p=0.059 for V105%.
The lymph node planning volumes LN_Sclav_Ax_R and LN_IMN_R were separately
evaluated for V4500cGy. As demonstrated in Figure 3, the percentage of V4500cGy for
LN_Sclav_Ax_R was greater with a statistically significant difference in means between IMRT
qod bolus (M=99.43, SD=0.73) and both VMAT full arc (M=98.86, SD=0.90), Z=-2.191,
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p=0.028 and VMAT partial arc (M=97.86, SD=1.69), Z=-2.803, p=0.005. There was not a
statistically significant difference in means for the LN_IMN_R between IMRT qod bolus
(M=99.74, SD=0.42) and VMAT full arc (M=99.18, SD=1.01), Z=-1.260, p=0.208. There was a
greater percentage of V4500cGy for LN_IMN_R for IMRT qod bolus (M=99.74, SD=0.42) with
a statistically significant difference in means compared to VMAT partial arc (M=98.43,
SD=1.71), Z=-2.192, p=0.028.
Organs at Risk
The ipsilateral lung, labeled Lung_R, was evaluated based on the following planning
objectives: V2000cGy, V1000cGy, and V500cGy. The means for all objectives are shown in
Figure 5. The difference in means for V2000cGy for IMRT qod bolus (M=27.6, SD=4.1) was
statistically significant compared to VMAT partial arc (M=34.4, SD=4.6), Z=-2.803, p=0.005,
but not compared to VMAT full arc (M=29.2, SD=6.1), Z=-0.866, p=0.386. The difference in
means for V1000cGy for IMRT qod bolus (M=43.8, SD=8.1) were also statistically significant
compared to VMAT partial arc (M=51.8, SD=5.9), Z=-2.803, p=0.005, but not compared to
VMAT full arc (M=50.7, SD=8.5), Z=-1.070, p=0.285. There was a statistically significant
difference in means for V500cGy for both VMAT partial arc (M=69.6, SD=8.0), Z=-2.701,
p=0.007 and VMAT full arc (M=78.9, SD=8.6), Z=-2.803, p=0.005 compared to IMRT qod
bolus (M=60.7, SD=10.0).
The heart was evaluated for D0.03cc, V1500cGy, and mean dose in cGy. The Wilcoxson
Signed Ranks tests did not reveal statistically significant difference in means for D0.03cc
between IMRT qod bolus (M=1331, SD=620) and VMAT full arc (M=1554, SD=417), Z=-0.663,
p=0.508 or VMAT partial arc (M=1354, SD=601), Z=-0.255, p=0.799. There was also no
statistically significant difference in the means for V1500cGy between IMRT qod bolus
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(M=0.052, SD=0.101) and VMAT full arc (M=0.185, SD=0.340), Z=-0.980, p=0.327 or VMAT
partial arc (M=0.175, SD=0.394), Z=-0.105, p=0.917. There was a statistically significant
difference in means for mean heart dose, see Figure 6. Mean heart dose was lower for IMRT qod
bolus (M=113, SD=44) compared to both VMAT full arc (M=315, SD=43), Z=-2.803, p=0.005
and VMAT partial arc (M=216, SD=80), Z=-2.803, p=0.005.
Skin Rind
The skin rind, which consisted of the rind of tissue between the body and the
PTV_Chestwall_R, was evaluated for each plan. As demonstrated by the box plot (Figure 7), the
skin rind mean dose (cGy) was higher for IMRT qod bolus (M=4493, SD=75) compared to both
VMAT plans. There was a statistically significant difference in means when compared to VMAT
full arc (M=3729, SD=91), Z=-2.803, p=0.005 and VMAT partial arc (M=3733, SD=146), Z=2.803, p=0.005.

Discussion
The purpose of this study is to determine if static field IMRT qod bolus and VMAT no
bolus plans in PMRT yield comparable dosimetric results. IMRT qod bolus plans were compared
to VMAT full arc plans and VMAT partial arc plans. Results comparing mean differences
showed statistical significance in some areas, rejecting the null hypothesis, and finding that there
is significant evidence of a difference between IMRT qod bolus and VMAT no bolus plans.
However, overall clinical significance needs to be evaluated to determine if VMAT remains a
plausible alternative to IMRT qod bolus in PMRT leading to decreased skin toxicity and shorter
treatment times for patients.
Planning Target Volumes
15

Planning target volumes include PTV_Chestwall_R, LN_Sclav_Ax_R, and LN_IMN_R.
As shown in Table 1 and Table 2, the mean scores of all three plans meet or exceed the goals as
defined by this Midwest Radiation Oncology center. Additionally, plan homogeneity as
measured by PTV_Chestwall_R Max, PTV_Chestwall_R 105%, and global max were evaluated.
The only of these measurements showing a statistically significant difference is between IMRT
qod bolus and VMAT full arc, with max being less for IMRT qod bolus. Overall, results are
comparable between IMRT qod bolus and VMAT no bolus plans. These results are similar to a
study by Zhang which compared VMAT with 0.5cm bolus to IMRT with 0.5cm bolus and found
a benefit of VMAT was improved target coverage and homogeneity. 11
Organs at Risk
Organs at risk include the ipsilateral lung, labeled Lung_R, and the heart. Constraints for
Lung_R were all lower for IMRT qod bolus when compared to both VMAT plans. There was a
statistically significant difference in means when comparing IMRT qod bolus to VMAT partial
arc for all constraints, and a statistically significant difference in means when comparing IMRT
qod bolus to VMAT full arc for V500cGy but not for V2000cGy or V1000cGy. Planning goals
for V2000cGy and V1000cGy were met for all plans. Goals for V500cGy were met for IMRT
qod bolus and exceeded for both VMAT plans. The clinical significance of V500cGy in breast
and chest wall irradiation has received attention in literature. A recent study looked at the risk of
radiation pneumonitis (RP) in patients with prior immune checkpoint inhibitors. This study
concluded that lung V500cGy is a weak predictor of RP in this setting. The author went on to
state that this is consistent with lung V500cGy as an unvalidated predictor of RP for the general
radiation patient population.12 This conclusion parallels a 2016 study which states that the
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increased low-dose-bath in VMAT for PMRT causes greatly increased lung V500cGy. However,
V2000cGy is the widely accepted predictor for RP.13
All the heart constraint goals were met for all plans. The only heart constraint that shows
a statistically significant difference in mean is the mean heart dose. With a goal of heart mean
<130-400cGy, Table 1 and Table 2 show that IMRT qod bolus mean scores fell below this range,
while VMAT plans fell within this range. This is contradictory to the literature which boasts
reduced mean dose and volumes of the lung and heart as benefits of VMAT as compared with
IMRT in PMRT.11 Overall, while results of this study do not prove superiority of any plan, the
dosimetric results for organs at risk reveal acceptable clinical results for all three plans.
Skin Rind
In addition to determining if static field IMRT qod bolus and VMAT no bolus plans in
PMRT yield comparable dosimetric results based on defined planning objectives, the purpose of
this study is to examine the skin dose received in these patients. In this study, the mean skin rind
is 4493cGy for static field IMRT qod bolus, 3729cGy for VMAT full arc, and 3733cGy for
VMAT partial arc, see Figure 8. Given as a percentage of the 5040cGy prescription, the mean
skin rind is receiving 89.1% for static field IMRT qod bolus, 74% for VMAT full arc, and 74.1%
for VMAT partial arc. These results point to a clear dosimetric difference with lower mean skin
dose in VMAT no bolus plans than in static field IMRT qod bolus plans. Based solely on this
information, the researcher could reject the null hypothesis and find that there is significant
evidence of a difference between IMRT qod bolus and VMAT no bolus plans. However, the
clinical significance of these results need to be further investigated. This Midwest Radiation
Oncology center does not have a defined goal for this structure. As such, an appropriate goal as
hypothesized by Nichol is used. Reported as the mean dose to a volume 3 to 5 mm beneath the
17

skin, Nichol states that “a 75%-of-prescription dose to the skin and subcutaneous tissues is
sufficient to eliminate residual disease and prevent local recurrence in 98% of patients without
skin involvement.”14 Incorporating Nichol’s hypothesis, the study results prove that VMAT no
bolus can reasonably reach the dose required to satisfy the primary goal of radiation therapy,
which is to eradicate disease. This further suggests that VMAT no bolus is an appropriate
treatment technique regarding adequate skin dose in PMRT.
Limitations and future research
The researcher acknowledges limitations based on the methods of the study. First, all
VMAT plans were normalized to 100% covers 90% of target volume. Outside of this limiting
factor, the mean score for V100% and V95% could have been greater which could have
influenced the statistically significant difference in means. The same can be said for
LN_Sclav_Ax_R and LN_IMN_R objectives of V4500cGy>95%. Future studies could
renormalize VMAT plans to the optimal balance of PTV coverage and OAR sparing in lieu of
consistency between VMAT full arc and VMAT partial arc plans.
Second, the original static field IMRT qod bolus plan was used as the basis for the
VMAT plans. This placed a limitation on the gantry and collimator angle selection. With more
freedom in gantry start and stop angle selection, plan homogeneity could have potentially been
further improved by decreasing separation between beams. Per the methods, avoidance sectors
were also pre-defined. With more freedom in avoidance sector selection, low-dose-bath could
potentially be further controlled, allowing for less dose to organs at risk. Future studies could
examine alternate methods of gantry angle and avoidance sector selection.
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This study could also be repeated with a focus on left sided breast cancer patients to
further examine if the heart mean is attainable in all cases of PMRT. Additionally, future studies
could examine the incorporation of flash in the treatment planning process as a way to increase
the skin dose to the recommended 75%-of-prescription14 from the study results of 74%-ofprescription.

Conclusion
Clinical significance needs to be weighed against statistical significance in a study of this
nature. Of clinical significance in this study is the achievement of planning goals. Lung
V500cGy was an unmet goal; however, data suggests that this objective may not be as significant
as once believed. While a statistically significant difference was found in skin dose, the resultant
skin dose of the VMAT plans is suggested to be appropriate for PMRT. Considering clinical
significance, results accept the null hypothesis, and this study finds that there is not significant
evidence of a difference between IMRT qod bolus and VMAT no bolus plans.
PMRT, except in cases of skin involvement and specific diagnosis, should be considered
without the use of bolus. This will lend to decreased skin dose in these patients and, in turn,
decreased skin toxicities without a decrease in local control. Additionally, VMAT has proven
comparable dosimetric results to static field IMRT, leading to a decrease in monitor units and
treatment time.
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Appendix
Table 1
Results of Wilcoxon Signed Ranks test for all planning objectives are shown for IMRT qod
bolus compared to VMAT full arc. Objective goals, where applicable, mean score and test
statistics are given. A p-value <0.05 was considered statistically significant. Statistically
significant results are displayed in bold text.
Planning Objective

PTV_Chestwall_R
V100% (%)
V95% (%)
Max (%)
V105% (%)
LN_Sclav_Ax_R
V4500cGy (%)
LN_IMN_R
V4500cGy (%)
Lung_R
V2000cGy (%)
V1000cGy (%)
V500cGy (%)
Heart
D0.03cc (cGy)
V1500cGy (%)
Mean (cGy)
Other (non-objectives)
Global Max (%)
Skin Rind Mean (cGy)

Goal

Mean Score
IMRT qod
VMAT full
bolus
arc

Test Statistics
Z

p

>95-90
>95
<110
<15-20

96.142
99.909
108.125
7.246

90.000
99.141
109.336
9.040

-2.805
-2.803
-2.090
-0.459

0.005
0.005
0.037
0.646

>95

99.425

98.861

-2.191

0.028

>95

99.742

99.183

-1.260

0.208

<30-35
<35-55
<50-65

27.571
43.849
60.736

29.159
50.736
78.875

-0.866
-1.070
-2.803

0.386
0.285
0.005

<2500
<10
<130-400

1330.700
0.052
113.230

1553.690
0.185
315.020

-0.663
-0.980
-2.803

0.508
0.327
0.005

111.500
4492.610

110.650
3729.200

-1.072
-2.803

0.284
0.005
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Table 2
Results of Wilcoxon Signed Ranks test for all planning objectives are shown for IMRT qod
bolus compared to VMAT partial arc. Objective goals, where applicable, mean scores, and test
statistics are given. A p-value <0.05 was considered statistically significant. Statistically
significant results are displayed in bold text.
Planning Objective

PTV_Chestwall_R
V100% (%)
V95% (%)
Max (%)
V105% (%)
LN_Sclav_Ax_R
V4500cGy (%)
LN_IMN_R
V4500cGy (%)
Lung_R
V2000cGy (%)
V1000cGy (%)
V500cGy (%)
Heart
D0.03cc (cGy)
V1500cGy (%)
Mean (cGy)
Other (non-objectives)
Global Max (%)
Skin Rind Mean (cGy)

Goal

Mean Score
IMRT qod
VMAT
bolus
partial arc

Test Statistics
Z

p

>95-90
>95
<110
<15-20

96.142
99.909
108.125
7.246

90.000
98.686
109.213
16.187

-2.805
-2.803
-1.580
-1.886

0.005
0.005
0.114
0.059

>95

99.425

97.863

-2.803

0.005

>95

99.742

98.429

-2.192

0.028

<30-35
<35-55
<50-65

27.571
43.849
60.736

34.416
51.840
69.594

-2.803
-2.803
-2.701

0.005
0.005
0.007

<2500
<10
<130-400

1330.700
0.052
113.230

1354.410
0.175
215.790

-0.255
-0.105
-2.803

0.799
0.917
0.005

111.500
4492.610

110.510
3732.490

-0.652
-2.803

0.515
0.005
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Figure 1
Images from Eclipse TPS showing beam angles in 3D for each plan. Shown from top to bottom:
static field IMRT qod bolus (bolus not pictured), VMAT full arc, and VMAT partial arc.
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Figure 2
Image from Eclipse TPS showing Skin Rind contour in pink. PTV_Chestwall_R is shown in red.

Figure 3
Box and whisker plot showing V95% (%) for PTV_Chestwall_R for IMRT qod bolus, VMAT
full arc, and VMAT partial arc plans.
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Figure 4
Box and whisker plot showing V4500cGy (%) for the lymph node planning volumes for IMRT
qod bolus, VMAT full arc, and VMAT partial arc plans.

Figure 5
Clustered column chart showing ipsilateral lung means (%) for V2000cGy, V1000cGy, and
V500cGy for IMRT qod bolus, VMAT full arc, and VMAT partial arc plans. The numbers at the
tops of the bars display the numeric value of that bar.

27

Figure 6
Box and whisker plot showing heart mean (cGy) for IMRT qod bolus, VMAT full arc, and
VMAT partial arc plans.

Figure 7
Box and whisker plot showing skin rind mean (cGy) for IMRT qod bolus, VMAT full arc, and
VMAT partial arc plans.
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Figure 8
Images from Eclipse TPS showing skin dose in color wash. Shown from top to bottom: static
field IMRT qod bolus (bolus not pictured), VMAT full arc, and VMAT partial arc.
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